208 related articles for article (PubMed ID: 32085394)
1. Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans.
Ryan SPP; Newman AA; Wilburn JR; Rhoades LD; Trikha SRJ; Godwin EC; Schoenberg HM; Battson ML; Ewell TR; Luckasen GJ; Biela LM; Melby CL; Bell C
Nutrients; 2020 Feb; 12(2):. PubMed ID: 32085394
[TBL] [Abstract][Full Text] [Related]
2. Influence of Sodium Glucose Cotransporter 2 Inhibition on Physiological Adaptation to Endurance Exercise Training.
Newman AA; Grimm NC; Wilburn JR; Schoenberg HM; Trikha SRJ; Luckasen GJ; Biela LM; Melby CL; Bell C
J Clin Endocrinol Metab; 2019 Jun; 104(6):1953-1966. PubMed ID: 30597042
[TBL] [Abstract][Full Text] [Related]
3. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.
Fadini GP; Bonora BM; Zatti G; Vitturi N; Iori E; Marescotti MC; Albiero M; Avogaro A
Cardiovasc Diabetol; 2017 Apr; 16(1):42. PubMed ID: 28376855
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease.
Sawada T; Uzu K; Hashimoto N; Onishi T; Takaya T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H
J Atheroscler Thromb; 2020 Jul; 27(7):644-656. PubMed ID: 31631099
[TBL] [Abstract][Full Text] [Related]
5. [Short-term Glucose Lowering Effects of Sodium-glucose Cotransporter 2 Inhibitors Confirmed by Flash Glucose Monitoring in Two Outpatients with Type 1 Diabetes].
Habu M; Okada Y; Kurozumi A; Tanaka Y
J UOEH; 2020; 42(4):359-364. PubMed ID: 33268615
[TBL] [Abstract][Full Text] [Related]
6. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
7. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
[TBL] [Abstract][Full Text] [Related]
8. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Sands AT; Zambrowicz BP; Rosenstock J; Lapuerta P; Bode BW; Garg SK; Buse JB; Banks P; Heptulla R; Rendell M; Cefalu WT; Strumph P
Diabetes Care; 2015 Jul; 38(7):1181-8. PubMed ID: 26049551
[TBL] [Abstract][Full Text] [Related]
9. Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
Millar PJ; Pathak V; Moffett RC; Pathak NM; Bjourson AJ; O'Kane MJ; Flatt PR; Gault VA
Mol Cell Endocrinol; 2016 Jan; 420():37-45. PubMed ID: 26607806
[TBL] [Abstract][Full Text] [Related]
10. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
[TBL] [Abstract][Full Text] [Related]
12. Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin.
Masuda D; Yamashita S
J Atheroscler Thromb; 2020 Jul; 27(7):637-638. PubMed ID: 32009076
[No Abstract] [Full Text] [Related]
13. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Mazidi M; Rezaie P; Gao HK; Kengne AP
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
[TBL] [Abstract][Full Text] [Related]
14. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
Schork A; Saynisch J; Vosseler A; Jaghutriz BA; Heyne N; Peter A; Häring HU; Stefan N; Fritsche A; Artunc F
Cardiovasc Diabetol; 2019 Apr; 18(1):46. PubMed ID: 30953516
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis.
Seidu S; Kunutsor SK; Cos X; Gillani S; Khunti K;
Prim Care Diabetes; 2018 Jun; 12(3):265-283. PubMed ID: 29482993
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin: A Review in Type 1 Diabetes.
Paik J; Blair HA
Drugs; 2019 Nov; 79(17):1877-1884. PubMed ID: 31664708
[TBL] [Abstract][Full Text] [Related]
17. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry.
Sawada Y; Izumida Y; Takeuchi Y; Aita Y; Wada N; Li E; Murayama Y; Piao X; Shikama A; Masuda Y; Nishi-Tatsumi M; Kubota M; Sekiya M; Matsuzaka T; Nakagawa Y; Sugano Y; Iwasaki H; Kobayashi K; Yatoh S; Suzuki H; Yagyu H; Kawakami Y; Kadowaki T; Shimano H; Yahagi N
Biochem Biophys Res Commun; 2017 Nov; 493(1):40-45. PubMed ID: 28928093
[TBL] [Abstract][Full Text] [Related]
18. Marked Hypertriglyceridemia in a Patient with type 2 Diabetes Receiving SGLT2 Inhibitors.
Senoo M; Tone A; Imai Y; Watanabe S; Kaneto M; Shimomura Y; Teshigawara S; Nakatou T
Acta Med Okayama; 2021 Feb; 75(1):103-107. PubMed ID: 33649621
[TBL] [Abstract][Full Text] [Related]
19. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
[TBL] [Abstract][Full Text] [Related]
20. Incorporating Milk Protein Isolate into an Energy-Restricted Western-Style Eating Pattern Augments Improvements in Blood Pressure and Triglycerides, but Not Body Composition Changes in Adults Classified as Overweight or Obese: A Randomized Controlled Trial.
Hudson JL; Zhou J; Kim JE; Campbell WW
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32235773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
